Akili made headlines in 2020 when it received Food and Drug Administration clearance for EndeavorRx, a video game designed to treat pediatric ADHD. Akili went public in 2022 in a deal that valued ...

Akili Interactive will release its video game treatment, EndeavorRx, for adults with ADHD, taking advantage of FDA flexibilities.

Akili noted in the results that EndeavorRx’s effects were largely consistent across both the 40% of participants who were also taking prescription medication for their ADHD and those who weren’t.

BOSTON—May 3, 2023 -- Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced topline results of the STARS-ADHD-Adult clinical trial evaluating the efficacy and safety of ...

Akili launches over-the-counter version of attention-improving video game for adults with ADHD By Andrea Park Jun 7, 2023 3:05pm Akili Interactive digital therapeutics ADHD Video Games ...

Akili’s marquee product is EndeavorRx, which they describe as a "first-of-its-kind attention treatment for children with ADHD, delivered through an action video game experience.” EndeavorRx is ...

Akili Inc AKLI announced the topline results of the STARS-ADHD-Adult trial evaluating EndeavorRx (AKL-T01) in adults with attention deficit/hyperactivity disorder (ADHD). The trial demonstrated ...

ADHD expert Dr. Scott Kollins joins Akili as chief medical officer, focused on advancing new treatments for cognitive impairments, starting in ADHD.

Akili, Inc., the leading digital medicine company behind EndeavorOTC™, today released results from a new study examining the ways in which ADHD impacts the U.S. workforce. Akili engaged ...

Akili Interactive, the company behind a video game-like prescription digital therapeutic for children with ADHD, reported its first full-year earnings since going public last year. The company ...